ClinicalTrials.gg
RecruitingNCT06925581Updated Dec 3, 2025

A Trial of HRS-6768 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of HRS-6768 in Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. subjects with solid tumors who have been or cytologically diagnosed with advanced - stage (unresectable or ) disease, have failed standard treatment (disease progression or intolerance), or lack effective treatment methods.
  3. There must be at least one evaluable lesion .
  4. 0-1
  5. The functions of major organs are in good condition.

Exclusion criteria

Exclusion Criteria:

  1. The patient has experienced significant weight loss within 28 days prior to signing the form.
  2. The patient has previously received radiopharmaceutical therapy or radioactive embolization, or has previously undergone any external beam radiotherapy (EBRT) involving more than 25% of the bone marrow, or has previously had EBRT directly applied to the kidneys, or has received any EBRT within 2 weeks before the first dose.
  3. The patient has received anti - tumor treatments such as surgery (excluding diagnostic and serous cavity effusion drainage), therapy, other antibody therapies, chemotherapy, targeted therapy, gene therapy, and vaccine therapy within 4 weeks before the first dose.
  4. The patient has had a severe infection ( > Grade 2) within 4 weeks before the first dose, such as severe pneumonia requiring hospitalization, bacteremia, and infectious complications. The patient has had symptoms and signs of infection within 2 weeks before the first dose that require intravenous antibiotic treatment (excluding cases of prophylactic antibiotic use).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    HRS-6768

    Drug: HRS-6768

Interventions

  • DrugHRS-6768

    HRS-6768

06

What researchers measure

Primary outcomes

  1. Phase 1:Dose-limiting toxicity (DLTs)

    To evaluate the safety and tolerability of HRS-6768 and determine the RP2D.

    Time frame: From first dose of study drug through at least 6 weeks

  2. Phase 1: recommended Phase 2 dose (RP2D)

    To evaluate the safety and tolerability of HRS-6768 and determine the RP2D.

    Time frame: From first dose of study drug to end of phase 1 treatment (up to approximately 1 years)

  3. Phase 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of HRS-6768

    Phase 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of HRS-6768

    Time frame: From first dose of study drug to end of treatment (up to approximately 2 years)

  4. Phase 2: Progression-free survival (PFS)

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

Secondary outcomes

  1. Phase 1/2: Absorbed dose (Gy) estimated in organs and tumor lesions

    To measure the radiation dosimetry of HRS-6768

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  2. Phase 1/2: Cmax of HRS-6768

    To evaluate the PK of HRS-6768

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  3. Phase 1/2: Tmax of HRS-6768

    To evaluate the PK of HRS-6768

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  4. Phase 1/2: Area under the curve (AUC) of HRS-6768

    To evaluate the PK of HRS-6768

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  5. Phase 1/2: clearance (CL) of HRS-6768

    To evaluate the PK of HRS-6768

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  6. Phase 1/2: Objective Response Rate (ORR)

    Objective response is defined as a best confirmed response of CR or PR by RECIST v1.1 as assessed by the investigator.

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 1 years)

  7. Phase 1/2: Duration of Response (DoR)

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  8. Phase 1/2: Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the frequency and percentage of participants with stable disease (SD) or CR or PR.

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  9. Phase 1: Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of first dose to the date of first evidence of radiographic progression or death due to any cause, whichever occurred first.

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

  10. Phase 1/2: Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of first dose to the date of death due to any cause.

    Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

07

Study locations

2 of 2 sites recruiting
  • Beijing Gaobo Hospital
    Beijing, Beijing Municipality 102206, China
    Recruiting
    • Lin Shen · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Xianjun Yu · Principal investigator
    • Shaoli Song · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 13, 2025
StartActual
Apr 24, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2027
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925581
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Apr 24, 2025
Primary completion
Apr 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Dec 3, 2025

Study contacts

Zengquan Gu
Contact
zengquan.gu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion